Alkermes plc $ALKS Shares Bought by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership grew its stake in shares of Alkermes plc (NASDAQ:ALKS) by 36.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,109,772 shares of the company’s stock after purchasing an additional 567,965 shares during the period. Artisan Partners Limited Partnership owned approximately 1.28% of Alkermes worth $63,293,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Capital Fund Management S.A. purchased a new stake in Alkermes during the second quarter worth $1,142,000. Public Sector Pension Investment Board raised its stake in shares of Alkermes by 11.6% during the 3rd quarter. Public Sector Pension Investment Board now owns 710,700 shares of the company’s stock worth $21,321,000 after buying an additional 73,787 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Alkermes by 38.9% in the 3rd quarter. New York State Common Retirement Fund now owns 195,999 shares of the company’s stock worth $5,880,000 after buying an additional 54,915 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Alkermes by 18.6% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 134,387 shares of the company’s stock valued at $4,032,000 after acquiring an additional 21,067 shares during the last quarter. Finally, Allianz Asset Management GmbH increased its holdings in Alkermes by 3,908.2% during the 3rd quarter. Allianz Asset Management GmbH now owns 524,795 shares of the company’s stock valued at $15,744,000 after acquiring an additional 511,702 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Activity at Alkermes

In other Alkermes news, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. This trade represents a 37.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. This represents a 13.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 148,148 shares of company stock worth $5,028,378 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

ALKS has been the topic of several recent research reports. Wells Fargo & Company upped their price target on shares of Alkermes from $37.00 to $43.00 and gave the company an “overweight” rating in a report on Thursday. HC Wainwright reaffirmed a “neutral” rating and issued a $43.00 target price on shares of Alkermes in a research note on Thursday. Wolfe Research assumed coverage on Alkermes in a research report on Monday. They set an “outperform” rating and a $45.00 price target for the company. Truist Financial upped their price objective on Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Bank of America increased their price objective on Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Stock Down 2.1%

ALKS stock opened at $30.10 on Friday. The stock has a market capitalization of $5.02 billion, a price-to-earnings ratio of 21.05 and a beta of 0.49. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The stock’s fifty day simple moving average is $31.54 and its 200-day simple moving average is $30.20.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The business had revenue of $384.55 million for the quarter, compared to analysts’ expectations of $380.44 million. During the same quarter last year, the company posted $1.05 earnings per share. The business’s quarterly revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.